Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omnia Biologics, a provider of manufacturing and process development services for companies engaged in the development of new biologics, and Korea-based pharmaceutical venture company Sumagen have successfully completed the cGMP manufacture of Sumagen's HIV/AIDS vaccine for a Phase I clinical trial.
Subscribe to our email newsletter
Dale VanderPutten, CEO of Omnia Biologics, said: “The team at Omnia is very pleased to have assisted Sumagen in this important effort addressing the new priorities of the path forward in the wake of the Step study. Sumagen, like many companies in the experimental biologics space, has had great difficulty in finding suitable contract manufacturing expertise to move their products into clinical trials.
“After the failure of other contract manufacturing organizations, we are happy that Omnia’s customer focused and product specialized services were able to satisfy 250% of their required yield on schedule.”